167 related articles for article (PubMed ID: 30537058)
21. RAS inhibitors' dose-dependent efficacy: myth or reality?
Taddei S
Curr Med Res Opin; 2015; 31(7):1245-56. PubMed ID: 25985327
[TBL] [Abstract][Full Text] [Related]
22. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
23. Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis.
Ye R; Hu Y; Yao A; Yang Y; Shi Y; Jiang Y; Zhang J
Int J Clin Pract; 2015 Jun; 69(6):674-81. PubMed ID: 25721930
[TBL] [Abstract][Full Text] [Related]
24. Beta-blockers for hypertension.
Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
[TBL] [Abstract][Full Text] [Related]
25. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
Musini VM; Fortin PM; Bassett K; Wright JM
Cochrane Database Syst Rev; 2008 Oct; (4):CD007066. PubMed ID: 18843743
[TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis.
Zhuang S; Wang HF; Li J; Wang HY; Wang X; Xing CM
Neurosci Lett; 2016 Jun; 624():53-61. PubMed ID: 27163195
[TBL] [Abstract][Full Text] [Related]
27. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.
Bangalore S; Fakheri R; Toklu B; Messerli FH
BMJ; 2016 Feb; 352():i438. PubMed ID: 26868137
[TBL] [Abstract][Full Text] [Related]
28. [Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
Kanorskiĭ SG
Kardiologiia; 2013; 53(10):89-95. PubMed ID: 24645559
[TBL] [Abstract][Full Text] [Related]
29. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation.
Hermida RC; Ayala DE; Fernández JR; Mojón A; Smolensky MH; Fabbian F; Portaluppi F
Chronobiol Int; 2013 Mar; 30(1-2):280-314. PubMed ID: 23077971
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
Ichikawa S; Takayama Y
Hypertens Res; 2001 Nov; 24(6):641-6. PubMed ID: 11768722
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Dorosch T; Ganzer CA; Lin M; Seifan A
Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
[TBL] [Abstract][Full Text] [Related]
32. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
[TBL] [Abstract][Full Text] [Related]
33. A systematic review on randomized control trials on rennin angiotensin aldosterone system inhibitors role in managing hypertension among hemodialysis patients.
Aftab RA; Khan AH; Adnan AS; Jannah N
Ren Fail; 2016; 38(3):474-80. PubMed ID: 26853680
[TBL] [Abstract][Full Text] [Related]
34. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
[TBL] [Abstract][Full Text] [Related]
35. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture.
Gao XM; Tsai A; Al-Sharea A; Su Y; Moore S; Han LP; Kiriazis H; Dart AM; Murphy AJ; Du XJ
Cardiovasc Drugs Ther; 2017 Apr; 31(2):145-156. PubMed ID: 28204966
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
38. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.
Thomopoulos C; Parati G; Zanchetti A
J Hypertens; 2015 Jul; 33(7):1321-41. PubMed ID: 26039526
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S; Volpe M
Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
[TBL] [Abstract][Full Text] [Related]
40. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials.
Thomopoulos C; Parati G; Zanchetti A
J Hypertens; 2016 Mar; 34(3):373-84; discussion 384. PubMed ID: 26780184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
